跳至主要内容
临床试验/EUCTR2018-002470-42-GB
EUCTR2018-002470-42-GB进行中(未招募)1 期

Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study - FluSHED-2

Imperial College London JRC Office0 个研究点目标入组 30 人开始时间: 2018年7月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Children age 6 years to 15 years +364 days of age on enrolment
  • 2.Children eligible to receive LAIV in accordance with Green Book advice [https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book]
  • 3.Written informed consent given by parent/ guardian and assent from child (both must be in place to proceed).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1.Contraindications to LAIV (notwithstanding allergy to egg protein), which include:
  • a.Hypersensitivity to the active ingredients, gelatin or gentamicin (a possible trace residue)
  • b.Previous systemic allergic reaction to LAIV
  • c.Previous allergic reaction to an influenza vaccine (not LAIV) is a relative contra-indication, which must be discussed with the CI to confirm patient suitability
  • d.Children/adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids*.
  • *High-dose steroids is defined as a treatment course for at least one month, equivalent to a dose greater than 20mg prednisolone per day (any age), or for children under 20kg, a dose greater than 1mg/kg/day.
  • NB: LAIV is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled/low-dose oral systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency.
  • e.Children / adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.
  • f.Pregnancy (determined by history). Where this cannot be confirmed, a urine pregnancy test will be performed.

研究者

发起方
Imperial College London JRC Office

相似试验